

BPH Global – The New Force in Seaweed Bio-Technology

INVESTOR PRESENTATION | MARCH 2026

BPH GLOBAL LIMITED (ASX: BP8)

www.bphglobal.com



Offer Information and Disclaimer

This investor presentation (the “presentation”) is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of BPH Global Limited (**BP8**). The presentation has been prepared to assist parties in making their own evaluation and for no other purpose. Parties should further carry out their own due diligence. It is not intended to form the basis of any investment decision or any other decisions.

No Representation or Warranty

No representation or warranty, express or implied, is or will be given by BP8 or any of its respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. This presentation does not purport to contain all of the information that may be required to evaluate a possible investment opportunity with respect to BP8, and does not constitute investment, tax or legal advice.

The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. BP8 disclaims any duty to update the information contained in this presentation. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM® or ® symbols, but parties assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

No Offer or Solicitation

This presentation shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities. No offer, sale or solicitation of any securities shall be made in any jurisdiction in which such offer, sale or solicitation would be prohibited. BP8 does not provide investors with personal advice that any investment made will be suitable for the investor’s personal circumstances or investment objectives. No representation or warranty is given by BP8 that any investment with respect to BP8 is suitable for the investor or that it will meet the investor’s investment objectives.

Eligible Recipients

This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation, you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice. This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Forward Looking Statements

This presentation contains “forward-looking statements”. These statements are based on management’s current expectations and beliefs, as well as on a number of assumptions concerning future events. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and all of which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements. BP8 may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements and the forward-looking statements should not be unduly relied upon. We do not undertake any obligation to update forward-looking statements following the date this presentation is made.

Any industry, market or other, similar data have been compiled from sources thought to be reliable, but have not been verified, and no assurance can be made as to their accuracy.

Risks

Please refer to Appendix 1 for Key Risks

Company Snapshot

Transforming Seaweed into Solutions for a Sustainable Future



Company Overview

ASX Ticker	BP8
Share Price (6 March 2026)	A\$0.002
Shares on Issue	2.35bn
Market Cap	\$4.7m
Cash	\$0.9m
Enterprise Value	\$3.8m
Top 20 Shareholding	49.5%

Major Shareholders	Holding	%
Matthew Leonard	121,166,668	5.15%
Atidim Investments Pty Ltd	107,162,506	4.55%
Apertus Capital Pty Ltd	105,498,941	4.48%
Peter Andrew Proska	100,066,667	4.25%
Adman Lanes Pty Ltd	85,000,000	3.61%

Board of Directors & Key Management



Matthew Leonard - Managing Director/CEO

Matthew is an accomplished and internationally proven business development professional. With over 12 years of outstanding record of achievement in demanding, complex and highly competitive markets. He possesses expertise across advertising, marketing and media event management sector, with recent focus on linking opportunities with high-net-worth individuals throughout Asia.



Francesco Cannavo – Executive Director

Francesco is an experienced public company director with significant business and investment experience working with companies operating across various industry sectors. Mr Cannavo has been instrumental in assisting many listed and unlisted companies achieve their growth potential by providing strategic advice on raising investment capital and completing strategic acquisitions.



Paul Stephenson – Non-Executive Chairman

Paul was a partner of HWL Ebsworth Lawyers for thirteen years before retiring from the partnership in 2017. Mr Stephenson remains a consultant with HWLE. Mr Stephenson specialises in public and private equity fundraising, initial public offerings, backdoor listings and reverse mergers (both in Australia and the United States), and mergers and acquisitions involving both private and listed companies



Deepak Jha – Director of Operations

With over 20 years of experience across Indonesia's trading, mining, manufacturing, and investment sectors, he specialises in driving growth in challenging and emerging markets. As a board member and shareholder at Mitra Agro Global, along with other ventures, he has successfully led large-scale projects with a focus on sustainable and profitable growth. His leadership approach emphasises building resilient teams and forming strategic partnerships to maximise long-term value

Investment Highlights

BPH Global is pioneering the integration of biotechnology, marine science, and sustainable development to deliver high-value products derived from seaweed, one of the planet's most versatile and renewable natural resources. BPH's approach spans the full value chain from sustainable farming and strategic sourcing to advanced processing and global marketing, ensuring traceability, quality and environmental responsibility at every stage.



Significant market opportunity, with the global seaweed market size of approximately \$28bn



Seaweed trading continues to strengthen, with revenues in the first 8 months of trading totalling \$2.15m, growing at an annualised CAGR of 310%




R&D Pipeline of high margin seaweed products, with clear path to near term commercialisation



Global partnerships including a commercial agreement with the Indonesian provincial government for seaweed supply and bio-stimulant manufacturing

A High-Growth \$28bn Global Seaweed Opportunity

Total Addressable Market¹



\$28bn

Total Addressable Market



12.3%

Annual Growth Rate



#1

Indonesia world largest seaweed producer




3

Target Markets
Asia, Europe, North America

BPH Global Strategic Overview

Seaweed Trading Performance

BPH continues to advance its strategy of increasing the proportion of sales conducted independently through its Makassar-based warehouse and operating platform



- ❖ Aggregate gross sales of **\$2.36 million AUD** within the first 9 months of trading operations
- ❖ Revenue growth of **156.5%** since the first month of trading.
- ❖ BPH remain focused on continuing the momentum into 2026 by expanding independent trading volumes through Makassar, strengthening supply chain resilience and sourcing networks, deepening domestic and international customer relationships; and progressing export readiness under the Company's Seaweed Export Licence

R&D & Commercialisation Project Timeline

PRINCIPAL R&D GOALS

Extraction of seaweed-based nutraceuticals and pharmaceutical ingredients to infuse into food, nutrition, healthcare, health supplements, cosmetics and personal care products, Bio stimulants and Biomass

Deployment of separate processing pathways to produce biofuels or extract critical minerals from seaweed biomass for sale into the energy, EV battery and minerals industry.

R&D & Commercialisation Program Highlights


R&D activity that is focused on value-added products that attract higher sales margins

SEAWEED BASED **BIO FUEL**

- ❑ **R&D program is focused on developing renewable biofuel opportunities from seaweed biomass generated through its existing operations.**
- ❑ **Seaweed biomass when broken down by fermentation in the Company's existing operations produces biohydrogen and other biogases as a by-product.**
- ❑ **As the Company's fermentation-based activities approach commercialisation, proposed to similarly upscale production of biogases in accordance with the outcomes of its R & D program.**
- ❑ **Seaweed biomass can also be processed using hydrothermal liquefaction (HTL) to produce biocrude, a renewable liquid biofuel.**
- ❑ **The Company's R&D program will focus on optimizing biogas production from fermentation and biocrude production from HTL processing of seaweed biomass.**
- ❑ **Potential ESG advantages of seaweed-derived biofuels compared with many land-based biofuel feedstocks, include no requirement for arable land, freshwater or fertiliser inputs.**

Seaweed Based Product Brand Development

Health Beverage, Nutraceuticals & Supplements



Probiotic/postbiotic Health
Seaweed based kaffir drink

Formulation completed /
Singapore
Polytechnic collaboration

Productive discussions with NZ
based water manufacturer /
global sales/marketing
distribution




Natural Formulations for Male Vitality & Performance Enhancement

Male Vitality Products


Integrated TCM & Marine Performance Formulation

- TCM-inspired botanical foundation combined with marine bioactive components
- Structured to support vascular function, stamina, and overall male vitality
- Clean-label, non-pharma positioning
- Designed for pre-activity or structured supplementation use
- Regulatory strategy includes pursuing TGA compliance in Australia prior to China market entry
- Currently exploring engagement with China-based e-commerce platforms for:
 - Direct-to-consumer distribution
 - Broader international market access



Proposed Seaweed based Biostimulant Platform

Developed Jointly by BPH Global × Temasek Polytechnic | Indonesia Production → Farmer Impact



Strategic Impact

- ❖ Higher crop yields and farmer income
- ❖ Reduced chemical fertilizer dependence
- ❖ Large-scale adoption through cooperative distribution
- ❖ Monetisation of Indonesia's seaweed resources

Animal Feed and Feed Supplement

Converting non-export grade seaweed into Animal Feed/Supplementation



R&D program launched to assess animal feed / feed supplement applications for non-export grade Raw Seaweed Biomass



Low-risk, low-cost approach leveraging existing Indonesia-based operations and sourced material (no immediate change to core trading/export business)



Value uplift from existing supply chain: monetise "out-of-spec" seaweed by improving utilisation, reducing waste, and supporting margin resilience



Key workstreams: nutritional & functional properties, animal health outcomes, and potential methane-reduction characteristics in feed formulations

Seaweed Bioremediation

Mass Scale Natural Solution Using Algal Biomass

Bio remediation of ocean areas adjacent to mineral smelters using BP8 seaweed technology

Discussions with Indonesian government & Indonesian based mining companies (min 12 month contacts)

Seaweed a hyperaccumulator of REE's & Critical Minerals

Ongoing R&D with Temasek Polytechnic & Marchwood Labs on identification & extraction



BPH Global (ASX: BP8) — Near-Term Catalysts



Transitioning from Seaweed Trading to High Value Marine
Biotechnology with strategic Partners

Seaweed Trading Growth

~A\$2.4M annual revenue run-rate
Indonesia sourcing network
Scale to >1000 MT/month potential
Target 2026-2027

Project Popeye – Men's Supplement

Seaweed-derived nutraceutical
R&D with Temasek Polytechnic
Commercialization target: Q42026

Seaweed Biostimulant

Agri-yield enhancement product
Indonesia farmer distribution
model
Field trials and pilot programs

Seaweed based Probiotic Drink

Launch in Partnership with
Beverage Company
Potential markets in China, SG &
ANZ
Test Market in next 3 months.
Control Main Ingredients
Processing

Fucoidan Extraction for Anti-Ageing

Seaweed-derived nutraceutical
MOU for commercialization with BRIN
(Indonesia)
Commercialisation target: Q4 2026

Growing Market Appreciation of Seaweed's Commercial Potential



Seaweed-based
Cattle Feed to reduce
methane emissions



Sea Forest Market
Cap \$140 Million –
Cattle feed



BPH GLOBAL LIMITED

(ASX:BP8) www.bphglobal.com

- **Chairman:** Paul Stephenson
- **Email:** paul.stephenson1@icloud.com
- **CEO:** Matthew Leonard
- **Email:** matthew@goldenventurecapital.com



Reinvigorated management driving a commercially sensible business plan



Deep expertise in sourcing and cultivating seaweed and the extraction of minerals, nano minerals and nutraceuticals from seaweed



Business focus on sales into new and existing markets and new business opportunities



New Business Opportunities sought and welcomed to grow the Company's operations and revenue

Appendix 1: Key Risks

There are specific risks which relate directly to the Company's activities. In addition, there are other general risks, many of which are largely beyond the control of the Company and the Directors.

The risks identified in this section, or other risk factors, may have a material impact on the financial performance of the Company and the market price of the Company's securities. The following is a summary of the more material matters to be considered and should be read in conjunction with specific matters referred to in the Company's announcements and reports. However, the summary is not exhaustive and potential investors should consult their professional advisors before deciding whether to apply for securities in the Company.

Business development and commercialisation

The Company is focused on producing foods and products which deliver Traditional Chinese Medicine (TCM)-based health outcomes and the development of technologies to enable the extraction of hydrogen and minerals from seaweed for use in the energy and battery industries. Regarding TCM products, the Company focuses on the research & development (R&D), production and commercialisation of bird's nest and plant-based products, including seaweed and sea plants and hemp, to produce sustainable bird's nest and plant-based protein foods and nutraceutical and pharmaceutical ingredients (including CBD extracted from Hemp) for utilisation in the food, nutrition, healthcare, health supplements, cosmetics and personal care industries. Regarding the energy and battery industries, the Company focuses its R&D on the extraction of hydrogen and minerals from seaweed, leveraging its technologies developed for the extraction of nutraceuticals from seaweed. There can be no guarantee that the resulting products or extracted hydrogen and minerals will be commercialised, will be competitive in their respective markets, or will perform satisfactorily to their intended application.

Funding

Any inability of the Company to obtain additional funding as required, including under the proposed capital raising, would have a material adverse effect on the Company's business, its financial condition and performance and its ability to continue as a going concern. Accordingly, there is a material uncertainty that may cast doubt on the Company's ability to continue as a going concern. Should the Company not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the Company's financial statements.

Research and development risk

In order to remain competitive, the Company intends to continue to undertake research and development. The Company makes no representation that any of its research into or development of its technologies and products will be successful or that its technologies will be developed into products that are commercially exploitable.

Intellectual Property Risks

The Company will give consideration to whether it will pursue patent protection in Singapore and other jurisdictions in relation to technologies it develops. However, there is no guarantee that any future patent applications filed by the Company will not infringe competitor patents or that any such patent applications will be granted by authorities in key jurisdictions, given that patents on similar subject matter may have been granted.

Regulatory

Changes in relevant taxes, legal and administration regimes, accounting practice and government policies may adversely affect the financial performance of the Company.

Reliance on key management

The responsibility of overseeing the day-to-day operations and the strategic management of the Company depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on the Company if one or more of these employees cease their employment.

Supply of Raw Materials

The Company may depend on the supply of raw materials to carry on elements of its business. Such supply may be disrupted because of weather, transportation and other matters outside the Company's control.

Product liability

The Company provides products for use in TCM and food products to deliver TCM-based health benefits, which are used and/or consumed by humans for therapeutic and other purposes. If the Company's product(s) causes damage or loss of life, claims may be made against the Company that it has supplied defective products.

Armed conflicts

The market price of the Company's Shares and Options may be adversely affected in the short to medium term by the economic uncertainty caused by the Ukraine conflict and the conflict in the Middle East.

Sovereign Risk

The Group's operations will continue to include a focus on markets in China and South East Asia, including but not limited to Singapore and Malaysia. Possible sovereign risks associated with operating in China and these South East Asian nations include, without limitation, changes in the terms of legislation, changes to taxation rates and concessions and changes in the ability to enforce legal rights. Any of these factors may, in the future, adversely affect the financial performance of the Company and the market price of the Company's Shares and listed Options.